JSPR logo

JASPER THERAPEUTICS INC

JSPRNASDAQ
🏆 #4780 by market capUS Equity
$805.08▲ $16.67 (+2.07%)
Simulated price
🔔
Track JSPR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$20M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
32
Weak
No chart data available for JSPR.

Trading Snapshot

Day Range
$799.38 – $818.43
52-Week Range
$0.32 – $2.69
Volume
$4.44B
Avg Volume
$3.24B
Shares Outstanding
33.3M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$586,145
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.58
Dividend Yield
—
Dilution (1yr)
+91.0%

Why Investors Own JSPR

  • ✓High-growth profile — revenue up -6.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 30% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

JSPR logo

JASPER THERAPEUTICS INC

JSPR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$81M▲ +5.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$77M▲ +22.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
28.7M▲ +91.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$27M▼ −$42M YoY
StockOtter · stockotter.space

About JASPER THERAPEUTICS INC

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
32/100

Analyst Price Target

ⓘ
Average Target
$1,028.34
▲ +27.7% Upside
High Target$1,232.14
Low Target$929.57
Based on 13 analysts

Latest News & Updates

🚀
Barron’s·2h ago

JASPER THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift JSPR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

JASPER THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.